Equities

Cryo-Cell International Inc

Cryo-Cell International Inc

Actions
Health CareHealth Care Providers
  • Price (USD)8.30
  • Today's Change0.43 / 5.46%
  • Shares traded15.51k
  • 1 Year change+91.69%
  • Beta0.4665
Data delayed at least 15 minutes, as of Nov 22 2024 01:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects CRYO-CELL International, Inc. share price to rise to 9.00 in the next year from the last price of 7.87.
High14.4%9.00
Med14.4%9.00
Low14.4%9.00

Earnings history & estimates in USD

On Oct 15, 2024, CRYO-CELL International, Inc. reported 3rd quarter 2024 earnings of 0.13 per share. This result exceeded the 0.02 expectation of the one analyst covering the company and exceeded last year's 3rd quarter results by 62.50%.
The next earnings announcement is expected on Feb 28, 2025.
Average growth rate+38.39%
CRYO-CELL International, Inc. reported annual 2023 losses of -1.14 per share on Feb 28, 2024.
Average growth rate+3.44%
More ▼

Revenue history & estimates in USD

Cryo-Cell International, Inc. had 3rd quarter 2024 revenues of 8.07m. This bettered the 7.98m estimate of the one analyst covering the company. This was 3.09% above the prior year's 3rd quarter results.
Average growth rate+0.62%
Cryo-Cell International, Inc. had revenues for the full year 2023 of 31.34m. This was 3.32% above the prior year's results.
Average growth rate+24.36%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.